Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PUMA BIOTECHNOLOGY, INC. Director's Dealing 2021

Jun 22, 2021

33488_dirs_2021-06-22_5e045d2f-5257-4fa3-ac24-8dc6f76fffee.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK: 0001401667
Period of Report: 2021-06-15

Reporting Person: Wong Alvin F (Chief Scientific Officer)

Holdings (Non-Derivative)

Security Shares Ownership
COMMON STOCK 7181 Direct
COMMON STOCK 963 Direct
COMMON STOCK 701 Direct
COMMON STOCK 2888 Direct
COMMON STOCK 6550 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
STOCK OPTION (RIGHT TO BUY) $28.63 2023-03-18 COMMON STOCK (14000) Direct
STOCK OPTION (RIGHT TO BUY) $112.80 2024-03-14 COMMON STOCK (10500) Direct
STOCK OPTION (RIGHT TO BUY) $217.38 2025-03-23 COMMON STOCK (10500) Direct
STOCK OPTION (RIGHT TO BUY) $73.57 2025-11-30 COMMON STOCK (7035) Direct
STOCK OPTION (RIGHT TO BUY) $39.50 2026-12-01 COMMON STOCK (10500) Direct

Footnotes

F1: Represents restricted stock units which, subject to the Reporting Person's continued service with the Company through the vesting date, shall vest in full on December 1, 2021.

F2: Represents restricted stock units which, subject to the Reporting Person's continued service with the Company through the applicable vesting date, shall vest with respect to one-half (1/2) of the restricted stock units on each of December 1, 2021 and June 1, 2022.

F3: Represents restricted stock units which, subject to the Reporting Person's continued service with the Company through the applicable vesting date, shall vest with respect to one-third (1/3) of the restricted stock units on each of December 1, 2021, June 1, 2022 and December 1, 2022.

F4: Represents restricted stock units which, subject to the Reporting Person's continued service with the Company through the applicable vesting date, shall vest with respect to (i) one-third (1/3) of the restricted stock units on December 1, 2021 and (ii) one-sixth (1/6) of the restricted stock units on each of June 1, 2022, December 1, 2022, June 1, 2023 and December 1, 2023.

F5: The option is currently exercisable.